<unk>  sometimes occurs for a few days or weeks after cataract surgery, but most such cases can be successfully treated with NSAID or cortisone eye drops. Prophylactic use of Nonsteroidal anti-inflammatory drugs has been reported to reduce the risk of<unk>  to some extent. Higher frequency use of topical steroids provides benefit in difficult to treat cases. Diabetic<unk>  may be treated with laser photocoagulation, reducing the chance of vision loss. In 2010, the US FDA approved the use of Lucentis intravitreal injections for<unk> . Iluvien, a sustained release intravitreal implant developed by Alimera Sciences, has been approved in Austria, Portugal and the U.K. for the treatment of vision impairment associated with chronic diabetic<unk>  (DME) considered insufficiently responsive to available therapies. Additional EU country approvals are anticipated. In 2013 Lucentis by intravitreal injection was approved by the National Institute for Health and Care Excellence in the UK for the treatment of<unk>  caused by diabetes and/or retinal vein occlusion. On July 29, 2014, Eylea (aflibercept), an intravitreal injection produced by Regeneron Pharmaceuticals Inc., was approved to treat DME in the United States.
Macular edema
Macular scarring
Corneal neovascularization
Macular corneal dystrophy
Corneal hydrops
Conjunctival concretion
Papilledema
Granular corneal dystrophy